Key points from article :
StarkAge Therapeutics (SATX), announces the appointment of Benjamin Le Calvé as Chief Scientific Officer, reporting to Pierre-Michel Bringer, CEO.
Le Calvé will lead the research activities of StarkAge Therapeutics and manage key collaborations with academic and industrial partners
– He joins from Celyad Oncology where he was Senior Scientist Early Development Group
– He brings expertise in senescence and a wealth of highly relevant international experience from academia and biopharmaceutical industry
As CSO, he will refine the current discovery strategy and implement it.
He will supervise the Lille-based research team and all key discovery projects and scientific operations.
He will oversee and supervise StarkAgeTx’s growing international IP portfolio.
